Fmr LLC reduced its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,463,780 shares of the biopharmaceutical company’s stock after selling 10,515 shares during the quarter. Fmr LLC owned approximately 7.11% of Amicus Therapeutics worth $162,777,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. P.R. Herzig & Co. Inc. acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $156,000. Arbor Wealth Management LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $144,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $179,000. Strs Ohio boosted its position in shares of Amicus Therapeutics by 32.2% during the 2nd quarter. Strs Ohio now owns 16,000 shares of the biopharmaceutical company’s stock worth $249,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in shares of Amicus Therapeutics by 33.5% during the 2nd quarter. Great West Life Assurance Co. Can now owns 20,494 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 5,148 shares in the last quarter.
In related news, major shareholder Life Sciences Maste Perceptive acquired 500,000 shares of the firm’s stock in a transaction on Wednesday, September 12th. The stock was bought at an average cost of $12.00 per share, with a total value of $6,000,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO William D. Baird III sold 10,000 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $12.23, for a total value of $122,300.00. Following the sale, the chief financial officer now directly owns 127,622 shares of the company’s stock, valued at $1,560,817.06. The disclosure for this sale can be found here. Over the last three months, insiders purchased 620,000 shares of company stock valued at $7,505,000. Insiders own 2.90% of the company’s stock.
Shares of NASDAQ FOLD opened at $9.92 on Friday. The stock has a market capitalization of $1.88 billion, a P/E ratio of -3.40 and a beta of 1.43. The company has a quick ratio of 9.03, a current ratio of 9.12 and a debt-to-equity ratio of 0.78. Amicus Therapeutics, Inc. has a 52-week low of $9.65 and a 52-week high of $17.62.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). The firm had revenue of $20.60 million during the quarter, compared to analyst estimates of $23.56 million. Amicus Therapeutics had a negative net margin of 463.82% and a negative return on equity of 52.03%. The firm’s revenue for the quarter was up 89.0% compared to the same quarter last year. During the same period last year, the company earned ($0.41) earnings per share. As a group, research analysts forecast that Amicus Therapeutics, Inc. will post -1.2 earnings per share for the current fiscal year.
FOLD has been the subject of several analyst reports. Zacks Investment Research cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. BidaskClub cut Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 18th. Chardan Capital cut Amicus Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $18.00 to $15.00 in a research report on Friday, August 17th. Cowen reissued a “buy” rating and issued a $31.00 target price on shares of Amicus Therapeutics in a research report on Friday, October 12th. Finally, ValuEngine raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $19.50.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Recommended Story: Outstanding Shares
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.